作者
Christian Lang, Peter Jaksch, Mir Alireza Hoda, György Lang, Thomas Staudinger, Edda Tschernko, Bernhard Zapletal, Silvana Geleff, Helmut Prosch, Riem Gawish, Sylvia Knapp, Oliver Robak, Florian Thalhammer, Alexander Indra, Markus Koestenberger, Robert Strassl, Thomas Klikovits, Kamran Ali, Gottfried Fischer, Walter Klepetko, Konrad Hoetzenecker, Peter Schellongowski
发表日期
2020/10/1
期刊
The Lancet Respiratory Medicine
卷号
8
期号
10
页码范围
1057-1060
出版商
Elsevier
简介
Most patients with COVID-19 have a mild or asymptomatic disease course; however, about 10% require admission to an intensive care unit (ICU) because of acute respiratory distress syndrome (ARDS). 1, 2 Mortality rates of up to 60% have been reported for this subgroup. 3, 4 Lung transplantation remains the ultimate treatment option for various chronic end-stage lung diseases. In addition, it can be considered as a salvage therapy for carefully selected patients who have severe treatment-refractory ARDS. 5 However, wide uncertainty exists as to whether lung transplantation could have a place in the treatment of severe COVID-19 and, if so, what the optimal timing for such a treatment should be. Herein, we report the first case of lung transplantation for a patient with a persistently positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) real-time RT-PCR test result.
On March 21, 2020, at a time …
引用总数
学术搜索中的文章